SNCA and Parkinson disease: Due to the genetic findings, researchers were led to develop antibodies against α-synuclein to use in histopathological sections of PD patient brains, discovering that α-synuclein was robustly expressed in LBs in the halo-like inclusions (Spillantini et al., 1998).